Inhibitor tripsina — разлика између измена
. |
(нема разлике)
|
Верзија на датум 28. октобар 2016. у 22:29
Inhibitor tripsina je tip inhibitora serinske proteaze koji redukuje biološku aktivnost tripsina. Tripsin je enzim koji učestvuje u razlaganju mnoštva različitih proteina. On učestvuje u procesu varenja kod ljudi i životinja. Proteazni inhibitori koji ometaju njegovu aktivnost mogu da imaju antinutriciono dejstvo.
 | Један корисник управо ради на овом чланку. Молимо остале кориснике да му допусте да заврши са радом. Ако имате коментаре и питања у вези са чланком, користите страницу за разговор.
Хвала на стрпљењу. Када радови буду завршени, овај шаблон ће бити уклоњен. Напомене
|
| Izvor | Inhibitor | Molekulska težina | Inhibitorna moć | Detalji |
|---|---|---|---|---|
| Krvna plazma | α1-antitripsin | 52 kDa | Takođe poznat kao inhibitor serumskog tripsina | |
| Lima pasulj | 8–10 kDa | 2.2 puta težina | Smeša šest različitih inhibitora | |
| Goveđi pankreas i pluća | Aprotinin | 6.5 kDa | 2.5 puta težina | Takođe poznat kao BPTI (bazni pankreasni tripsinski inhibitor) i Kunitz inhibitor. |
| Raw avian egg white | Ovomucin | 8–10 kDa | 1.2 puta težina | Ovomukoidi su smeše nekoliko različitih glikoproteinskih proteaznih inhibitora |
| Soja | 20.7–22.3 kDa | 1.2 puta težina | Smeša nekoliko različitih inhibitora. Svi se isto tako vezuju za himotripsin, mada u manjoj meri. |
Jedna studija iz 2010. godine je pokazala da proteazni inhibitor iz jaja slatkovodnog puža Pomacea canaliculata deluje kao inhibitor tripsina sa proteazama potencijalnih predatora. To su prvi direktni dokazi tog mehanizma u životinjskom carstvu.[1]
Klinički značaj
The peptide tumor-associated trypsin inhibitor (TATI) has been used as a marker of mucinous ovarian carcinoma, urothelial carcinoma, and renal cell carcinoma. TATI is metabolised by the kidneys and is, thus, elevated in patients with renal failure. It may be elevated in nonneoplastic processes such as pancreatitis and can be used as a prognostic marker in this setting (levels above 70 micrograms/L are associated with poor prognosis).
Fifty percent of stage I mucinous ovarian carcinomas are associated with elevated TATI, and nearly 100% of stage IV tumors show elevated TATI.
Eighty-five to 95% of pancreatic adenocarcinomas are associated with increased TATI (but elevation in pancreatitis limits the clinical utility of TATI in this setting; see above).
Sixty percent of gastric adenocarcinomas show elevated TATI, in particular tumors of diffusely infiltrative/signet ring type. TATI, thus, complements CEA, which is elevated exclusively in intestinal type adenocarcinoma of the stomach.
In urothelial carcinoma, TATI expression varies with stage, ranging from 20% in low-stage tumors to 80% of high-stage tumors.
TATI sensitivity in the setting of renal cell carcinoma is approximately 70%. Elevated TATI is more likely to be seen in patients with advanced-stage disease.
In nearly all tumor types studied, TATI is a marker of poor prognosis.[2]
Reference
- ^ Dreon M. S., Ituarte S. & Heras H. (2010). "The Role of the Proteinase Inhibitor Ovorubin in Apple Snail Eggs Resembles Plant Embryo Defense against Predation". PLoS ONE 5(12): e15059. doi:10.1371/journal.pone.0015059.
- ^ De Mais, Daniel. ASCP Quick Compendium of Clinical Pathology, 2nd Ed. ASCP Press 2009.
Literatura
- Jones et al., Biochem., 2, 66, (1963)
- Lineweaver and Murray JBC, 171, 565 (1947)
- Kunitz and Northrop J. Gen. Physiol., 19, 991 (1936)
- Fraenkel-Conrat, et al., Arch. Biochem. Biophys., 37, 393 (1952)
- Frattali, V., and Steiner, R.: Biochem., 7, 521 (1968)
Spoljašnje veze
- Trypsin+inhibitors на US National Library of Medicine Medical Subject Headings (MeSH)